KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of KN046 plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin in subjects with advanced squamous NSCLC who have not previously received systemic treatment.
Squamous Non-small-cell Lung Cancer
DRUG: KN046|DRUG: KN046 placebo
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging, PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first., up to 2 years|Overall Survival (OS), OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the interim analysis were censored at the date of the last follow-up., up to 3 years
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigators, PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first., up to 2 years
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of KN046 plus paclitaxel and carboplatin versus placebo plus paclitaxel and carboplatin in subjects with advanced squamous NSCLC who have not previously received systemic treatment.